摘要
目的探讨阿托伐他汀对血管紧张素Ⅱ诱导人脐静脉内皮细胞衰老中凋亡调控基因Bcl-2、Bax及Bcl-2/Bax蛋白表达的影响。方法体外培养人脐静脉内皮细胞,用血管紧张素Ⅱ(AngⅡ)及阿托伐他汀干预,分为对照组、血管紧张素Ⅱ诱导组及阿托伐他汀组,采用β-半乳糖苷酶染色和流式细胞术鉴定细胞衰老,并利用免疫细胞化学染色法、Western blot法分析各组凋亡相关基因Bcl-2、Bax蛋白表达水平。结果血管紧张素Ⅱ诱导组存活的细胞数与对照组相比81.90%±0.04%;约80%的细胞呈现β-半乳糖苷酶活性阳性染色和流式细胞仪检测细胞周期停滞于G0/G1,证实细胞衰老;与血管紧张素Ⅱ诱导组相比,阿托伐他汀组Bcl-2蛋白表达水平明显增高(P<0.05),Bax蛋白表达水平降低(P<0.05),Bcl-2/Bax比值显著增加(P<0.05)。结论血管紧张素Ⅱ可诱导体外培养的人脐静脉内皮细胞老化,从而复制细胞衰老。Bcl-2、Bax蛋白表达的失衡可能是血管衰老的重要分子机制之一,阿托伐他汀有一定的延缓血管衰老的作用。
Aim To explore the effects of Atorvastatin on the senescence in human umbilical vein endothelial cells (HUVEC) induced by angiotensin Ⅱ( Ang Ⅱ ) and to study its potential molecular mechanism. Method The HUVEC were cultured in vitro and divided into 3 groups, the control group, Ang H group ( stimulated and intervened by Ang Ⅱ10 -6mol/L for 48 h) ,Atorvastatin group ( 10-3mol/L Atorvastatin was added to cell 1 h before 10-6mol/L Ang Ⅱ ). β-Gal stain and ceil cycle analysis were used to identify cell aging status;and the expression of apoptosis-asseciation genes Bcl-2 and Bax were detected by immunocytochemistry, and Western blot. Results Ang H stimulation enhanced the positive cell number of β-gal stained HUVEC, depressed cell proliferation. The Ang Ⅱ group inhibited the expression of Bcl-2 protein and increased the expression of Bax protein compared with the Atorvastatin group markedly (P 〈 0. 05 ), Bcl- 2/Bax was decreased significantly ( P 〈 0. 05 ) in the Ang H group. The Atorvastatin group increased the expression of Bcl- 2 protein and decreased the expression of Bax protein compared with the Ang Ⅱ group evidently ( P 〈 0. 05 ), Bcl-2/Bax was increased significantly(P 〈 0. 05) in the Atorvastatin group. Conclusions Atorvastatin probably delay the senescence of vascular endothelial cell induced by Ang Ⅱ through regulating the expression of Bcl-2/Bax protein.
出处
《中国动脉硬化杂志》
CAS
CSCD
北大核心
2012年第1期11-15,共5页
Chinese Journal of Arteriosclerosis
基金
国家973重点基础研究发展规划基金资助项目(2007CB507405)
中华医学会临床医学科研专项资金-动脉粥样硬化研究资金资助(09010530208)
辽宁省科学技术研究项目(20091104)
沈阳市科学技术计划项目(F10-205-1-44)